FDA Guidance Raises Concerns about Y-mAbs’ Neuroblastoma Treatment before Adcomm

FDA scientists raised questions about the efficacy of Y-mAbs Therapeutics’ experimental neuroblastoma treatment, omburtamab, two days before the regulator’s Oncologic Drugs Advisory Committee meets to examine data supporting the BLA.